CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...
CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders. Its ...
Philadelphia, November 16, 2023 – Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This ...
Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors No significant financial relationships to ...
Multiple sclerosis (MS) is recognized as one of the most prevalent neurological diseases among young adults, with symptoms typically emerging between ages 20 to 40 years. The condition is ...
—A new study looked at adult Black and White patients with a diagnosis of MS or NMOSD, with the goal of examining differences in B-cell reemergence after anti-CD20 infusions. Here’s what the experts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback